title: The effect of liraglutide on endothelial function in patients with type 2 diabetes.
abstract: This single-centre, 12-week, double-blind, placebo-controlled trial assessed how the human glucagon-like-peptide 1 analogue liraglutide impacted endothelial function in adult patients (n = 49) with type 2 diabetes and no overt cardiovascular disease. Patients were randomized to liraglutide, placebo or glimepiride. At baseline and Week 12, venous occlusion plethysmography was used to measure forearm blood flow (FBF) in response to acetylcholine (ACh) and sodium nitroprusside (SNP) before and after (L)-N(G)-monomethyl arginine (L-NMMA) infusion. At Week 12, ACh-mediated FBF increased with liraglutide and decreased with placebo; however, the between-treatment difference was not significant (p = 0.055). Inhibition of ACh-mediated FBF after L-NMMA infusion increased with liraglutide and decreased with placebo; this between-treatment difference was also not significant (p = 0.149). No change in FBF was observed with SNP. Liraglutide did not significantly impact endothelium-dependent vasodilation after 12 weeks; however, additional investigations looking at the effect of liraglutide on endothelial function in alternative vasculature and during the postprandial period are warranted.
authors.affiliation: Mayo Clinic, Rochester, MN, USA.
authors.forename: Debashis
authors.initials: D
authors.lastname: Nandy
authors.affiliation: Mayo Clinic, Rochester, MN, USA.
authors.forename: Christopher
authors.initials: C
authors.lastname: Johnson
authors.affiliation: Mayo Clinic, Rochester, MN, USA.
authors.forename: Rita
authors.initials: R
authors.lastname: Basu
authors.affiliation: Mayo Clinic, Rochester, MN, USA.
authors.forename: Michael
authors.initials: M
authors.lastname: Joyner
authors.affiliation: Novo Nordisk, Inc., Plainsboro, NJ, USA.
authors.forename: Jason
authors.initials: J
authors.lastname: Brett
authors.affiliation: Novo Nordisk A/S, Søborg, Denmark.
authors.forename: Claus Bo
authors.initials: CB
authors.lastname: Svendsen
authors.affiliation: Mayo Clinic, Rochester, MN, USA basu.ananda@mayo.edu.
authors.forename: Ananda
authors.initials: A
authors.lastname: Basu
mesh_terms: D000109:Acetylcholine; D000368:Aged; D001786:Blood Glucose / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D002096:C-Peptide / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D004730:Endothelium, Vascular / Q000187:drug effects*; D005260:Female; D005934:Glucagon / Q000097:blood; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D015309:Glucose Clamp Technique; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D007328:Insulin / Q000097:blood; D008055:Lipids / Q000097:blood; D000069450:Liraglutide; D008297:Male; D008875:Middle Aged; D009599:Nitroprusside; D010991:Plethysmography
chemical_list: D001786:Blood Glucose; D002096:C-Peptide; D007004:Hypoglycemic Agents; D007328:Insulin; D008055:Lipids; D009599:Nitroprusside; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1; D005934:Glucagon; D000109:Acetylcholine
keywords: Glucagon-like peptide-1; endothelial function; liraglutide